Cerba HealthCare Changes Its Governance and Appoints Emmanuel Ligner Group Chief Executive Officer
Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group. The Group has also strengthened its Supervisory Board with the appointment of Paul Navarre as Chairman and the appointments of Dr. Nuala Murphy and Benoît Ribadeau-Dumas. Their international track records and deep healthcare expertise will support the Group’s expansion in Europe, Africa and North America in clinical pathology for clinical trials, routine and specialty clinical pathology. Cerba HealthCare aims to remain at the forefront of medical innovation to help develop new treatments and improve patient health.
Emmanuel Ligner, Group Chief Executive Officer, said: « Cerba HealthCare is a leading company in the field of medical diagnostics as evidenced by the Group’s growth and the importance it has placed on innovation since its very inception. I am honored to join Cerba HealthCare at this key moment in its history where the expertise of the Group -ranging from routine clinical pathology to clinical pathology for assays- makes it possible to meet the challenges of the personalized medicine of tomorrow. I look forward to joining the management team and meeting with the employees. Together, we will build the next chapter of Cerba HealthCare. »
Paul Navarre, Chairman of the Supervisory Board, adds: « I am very pleased to join the Supervisory Board of Cerba HealthCare, which will invest all its energy and skills into the implementation of our international deployment strategy and the completion of the transformation plan already underway. With Emmanuel’s appointment, the Group is in an excellent position to carry out its growth strategy, powered by its ability to innovate and consolidate its positions across businesses and geographic markets. »
Jérôme Thill, Senior Advisor and former Chief Executive Officer of the Group, adds: « As I step down as Chief Executive Officer, I would like to thank all of Cerba HealthCare’s teams and partners. I wish Emmanuel Ligner and the whole team every success in their new roles. »
Emmanuel Ligner will join Cerba HealthCare on March 1st, 2024. Until then, Paul Navarre will act as the Group’s CEO, with the support of Jérôme Thill, as Senior Advisor, and of Philippe Buhl, as Managing Director.
####
Emmanuel Ligner has had a distinguished career in the healthcare sector. As Chairman and CEO of Cytiva (formerly GE HealthCare Life Sciences) since 2017, he has accelerated the growth trajectory of the group, which doubled sales in recent years. Before taking the helm at Cytiva, Emmanuel held a number of key positions in North America, Europe, the Middle East and Africa. Emmanuel began his career in the late 90s in Japan with Otsuka Pharmaceutical before joining Abbott.
Paul Navarre spent 30 years in management positions at Procter & Gamble, Allergan (President) and Ferring Inc (CEO). He is currently a member of the board of directors of several companies around the world (LEO Pharma, HTL, Hallura) and advises private equity funds.
Dr. Nuala Murphy, a neuroscientist by training, has held senior international positions in the pharmaceutical industry, most recently as President of Development and Commercialization at ICON Plc. In addition to joining the Supervisory Board of Cerba HealthCare, Nuala will take on the role of Executive Chair of Cerba Research.
Benoît Ribadeau-Dumas spent 15 years in senior management positions in the industry sector (Thales, CGG, Zodiac Aerospace), before becoming Chief of Staff to French Prime Minister Edouard Philippe from 2017 to 2020. Benoît is now Managing Director at Exor and a member of various boards, including Stellantis, Iveco, Institut Mérieux and Galileo Global Education.
####
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109943506/en/
Contact information
Press contact:
Cerba HealthCare
Emmanuelle Saby
+33 6 09 10 76 10
emmanuelle.saby@cerbahealthcare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logo Established for the “Japan Creator Support Fund” to Support the Global Success of Japan’s Next-Generation Creators and Artists30.6.2025 09:00:00 EEST | Press release
The Japan Arts Council (President: Mariko Hasegawa), with funding from the Agency for Cultural Affairs, has established the Japan Creator Support Fund to support projects nurturing Japan’s diverse creators and artists, and to support cultural facilities’ function enhancement. We are pleased to announce that the logo for the Fund has been established and that the English-language global website, which is promoting this project overseas, has been officially launched on Monday, June 30, 2025. A promotional video for international audiences is also now available on the website. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627404244/en/ From the top left are the individual logos for the following support programs: the Creator & Artist Development Support Program [FOR CREATORS], the Support Program for Cultural Facilities Function Enhancement [FOR CULTURAL FACILITIES], the Creator Support Program (Program Development & Implem
From Waste to Strategic Metals: Circular Materials Achieves First Industrial-Scale Recoveries Under the Critical Raw Materials Act30.6.2025 09:00:00 EEST | Press release
Circular Materials announces two major milestones under the Critical Raw Materials Act: the recovery from industrial wastewater of the first kilogram of ruthenium and the first ton of nickel, preventing the release of heavy metals into the environment. These results were secured through strong collaborations with two leading companies in surface treatments: LEM, core company of the LEM INDUSTRIES Group, specialized in the luxury sector, and Argos Surface Technologies Group, a leader in industrial coatings. This success comes just a few months after the European Commission recognized Recover-IT as a strategic project, confirming the pivotal role of Circular Materials in securing critical raw material supplies, increasing recycling, and reducing the EU’s dependence on imports. Ruthenium and Nickel: crucial metals for a sustainable future Ruthenium, a noble metal from the platinum group, is essential for cutting-edge sectors such as advanced electronics, green hydrogen production, fine ch
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom